Effect of subconjunctivally injected, liposome-bound, low-molecular-weight heparin on the absorption rate of subconjunctival hemorrhage in rabbits

Investigative Ophthalmology and Visual Science

Volumn 47, Issue 9, 2006, Pages 3968-3974

  Moon, Jun Woong ^a   Song, Yun Kyoung ^b,c   Jee, Jun Pil ^b   Kim, Chong Kook ^b   Choung, Ho Kyung ^b   Hwang, Jeong Min ^a,d  

^a Seoul National University Hospital   (South Korea)

^b Seoul National University   (South Korea)

^c Korea Food and Drug Administration   (South Korea)

^d Seoul National University Bundang Hospital   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

LIPOSOME; LOW MOLECULAR WEIGHT HEPARIN; DRUG CARRIER; FIBRINOLYTIC AGENT;

ABSORPTION; ANALYZER; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CAMERA; COMPARATIVE STUDY; CONJUNCTIVAL HEMORRHAGE; CONTROLLED STUDY; DRUG DOSAGE FORM COMPARISON; DRUG EFFECT; DRUG FORMULATION; IMAGE ANALYSIS; MEASUREMENT; NONHUMAN; PRIORITY JOURNAL; RABBIT; STATISTICAL SIGNIFICANCE; ANIMAL; CONJUNCTIVA; CONJUNCTIVA DISEASE; DISEASE MODEL; INJECTION; INTRAOCULAR HEMORRHAGE; METABOLISM; PATHOPHYSIOLOGY; TIME; VASCULARIZATION;

ABSORPTION; ANIMALS; CONJUNCTIVA; CONJUNCTIVAL DISEASES; DISEASE MODELS, ANIMAL; DRUG CARRIERS; EYE HEMORRHAGE; FIBRINOLYTIC AGENTS; HEPARIN, LOW-MOLECULAR-WEIGHT; INJECTIONS; LIPOSOMES; RABBITS; TIME FACTORS;

EID: 33749123463     PISSN: 01460404     EISSN: None     Source Type: Journal    
DOI: 10.1167/iovs.05-1345     Document Type: Article

References (26)

1. Richards RD. Subconjunctival hemorrhage: treatment with air therapy. Eye Ear Nose Throat Monogr. 1965;44:59.
2. Kleinschmidt K, Charles R. Pharmacology of low molecular weight heparins. Emerg Med Clin North Am. 2001;19:1025-1049.
3. Klein W, Buchwald A, Hillis SE, et al. Comparison of low-molecular-weight heparin with unfractionated heparin acutely and with placebo for 6 weeks in the management of unstable coronary artery disease. Circulation. 1997;96:61-68.
4. Simonneau G, Sors H, Charbonnier B, et al. A comparison of low-molecular-weight heparin with unfractionated heparin for acute pulmonary embolism. N Engl J Med. 1997;337:663-669.
5. Farced J, Jeske W, Hoppensteadt D, Clarizio R, Walenga JM. Low-molecular-weight heparins: pharmacologic profile and product differentiation. Am J Cardiol. 1998;82:3L-10L.
6. Hiraoka N, Allen E, Apel IJ, Gyetko MR, Weiss SJ. Matrix metalloproteinases regulate neovascularization by acting as pericellular fibrinolysins. Cell. 1998;95:365-377.
7. Nesheim M, Wang W, Boffa M, Nagashima M, Morser J, Bajzar L. Thrombin, thrombomodulin and TAFI in the molecular link between coagulation and fibrinolysis. Thromb Haemost. 1997;78:386-391.
8. Assil KK, Frucht-Perry J, Ziegler E, Schanzlin DJ, Schneiderman T, Weinreb RN. Tobramycin liposomes: single subconjunctival therapy of pseudomonal keratitis. Invest Ophthalmol Vis. Sci. 1991;32:3216-3220.
9. Barza M, Baum J, Szoka F Jr. Pharmacokinetics of subconjunctival liposome-encapsulated gentamicin in normal rabbit eyes. Invest Ophthalmol Vis. Sci. 1984;25:486-490.
10. Law SL, Hung HY. Properties of acyclovir-containing liposomes for potential ocular delivery. Int J Pharm. 1998;161:253-259.
11. Touitou E, Dayan N, Bergelson L, Godin B, Eliaz M. Ethosomes: novel vesicular carriers for enhanced delivery: characterization and skin penetration properties. J Control Rel. 2000;65:403-418.
12. Jiao Y, Ubrich N, Hoffart V, et al. Anticoagulant activity of heparin following oral administration of heparin-loaded microparticles in rabbits. J Pharm Sci. 2002;91:760-768.
13. Bajzar L, Nesheim ME, Tracy PB. The profibrinolytic effect of activated protein Cin clots formed from plasma is TAFI-dependent. Blood. 1996;88:2093-2100.
14. Perry WF. Heparin-activated lipase in diabetic, atherosclerotic and healthy subjects. Clin Chim Acta. 1967;16:189-194.
15. Presta M, Dell'era P, Mitola S, Moroni E, Ronca R, Rusnati M. Fibroblast growth factor/fibroblast growth factor receptor system in angiogenesis. Cytokine Growth Factor Rev. 2005;16:159-178.
16. Liotta LA, Steeg PS, Stetler-Stevenson WG. Cancer metastasis and angiogenesis: an imbalance of positive and negative regulation. Cell. 1991;64:327-336.
17. Kunitada S, FitzGerald GA, Fitzgerald DJ. Inhibition of clot lysis and decreased binding of tissue-type plasminogen activator as a consequence of clot retraction. Blood. 1992;79:1420-1427.
18. Hirsh J, Anand SS, Halperin JL, Fuster V. Mechanism of action and pharmacology of unfractionated heparin. Arterioscler Thromb Vasc Biol. 2001;21:1094-1096.
19. Assu KK, Hartzer M, Weinreb RN, Nehorayan M, Ward T, Blumenkranz M. Liposome suppression of proliferative vitreoretinopathy. Invest Ophthalmol Vis. Sci. 1991;32:2891-2897.
20. Ambati J, Gragoudas ES, Miller JW, et al. Transscleral delivery of bioactive protein to the choroid and retina. Invest Ophthalmol Vis Sci. 2000;41:1186-1191.
21. Barza M, Stuart M, Szoka F Jr. Effect of size and lipid composition on the pharmacokinetics of intravitreal liposomes. Invest Ophthalmol Vis Sci. 1987;28:893-900.
22. Fitzgerald P, Hadgraft J, Wilson CG. A gamma scintigraphic evaluation of the precorneal residence of liposomal formulations in the rabbit. J Pharm Pharmacol. 1987;39:487-490.
23. Song YK, Kim CK. Topical delivery of low-molecular-weight heparin with surface-charged flexible liposomes. Biomatertals. 2006;27:271-280.
24. Hirsh J, Warkentin TE, Raschke R, Granger C, Ohman EM, Dalen JE. Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing considerations, monitoring, efficacy, and safety. Chest. 1998;114:4898-5108.
25. Estes JW. Clinical pharmacokinetics of heparin. Clin Pharmacokinet. 1980;5:204-220.
26. Heit J. Low-molecular-weight heparin: biochemistry, pharmacology, and concurrent drug precautions. Reg Anesth Pain Med. 1998;23:135-139.